08:45 – 09:00  Welcome and introduction
  Medical oncologist - Aristotelis Bamias, Athens (GR)
  Radiation oncologist - Peter Hoskin, Northwood and Manchester (GB)
  Urologist - Arnulf Stenzl, Tübingen (DE)

09:00 - 10:30  Prostate cancer staging in 2021: Where are we, where are we going? (plenary 1)
  Chairs:  Radiologist – Raymond Oyen, Leuven (BE)
           Radiation oncologist - Michael Pinkawa, Bonn (DE)
           Urologist – Philip Corford, Liverpool (GB)

09:00 - 09:10  State of the Art lecture: Strengths and limitations of PSMA PET for primary staging
  Nuclear medicine physician - Stefano Fanti, Bologna (IT)

09:10 - 09:30  Should PSMA PET impact on treatment in newly diagnosed PCa (debate yes vs no)?
  Yes: Urologist - Tobias Maurer, Hamburg (DE)
  No: Urologist - Jochen Walz, Marseille (FR)

09:30 - 09:40  Optimal staging approach in men recurring after primary treatment
  Urologist - Declan Murphy, Melbourne (AU)

09:40 - 09:50  How to use imaging for treatment monitoring in metastatic prostate cancer
  Radiologist – Tavernaraki Ekaterini, Athens (GR)

09:50 - 10:00  Summary and evidence based recommendations
  Urologist - Philip Corford, Liverpool (GB)

10:00 - 10:30  Discussion

10.30 - 11.00  Coffee break and e-poster viewing

11:00 - 12:45  Prostate cancer : multi-disciplinary case discussions from local to systemic disease (plenary 2)
  Chairs:  Radiation oncologist - Pierre Blanchard, Villejuif (FR)
           Urologist - Steven Joniau, Leuven (BE)

11:00 - 11:35  Multidisciplinary case discussion: Active surveillance
  Moderator and Case presenter: Urologist - Tobias Maurer, Hamburg (DE)
  Case discussants:  Pathologist - Eva Compérat, Paris (FR)
                   Urologist - Veeru Kasivisvanathan, London (GB)
                   Urologist - Juan Gomez Rivas, Madrid (ES)

11:35 - 12:10  Multidisciplinary case discussion: Oligo recurrent disease
  Moderator and Case presenter: Urologist - Alberto Briganti, Milan (IT)
  Case discussants:  Internal medicine – Stefano Fanti, Bologna (IT)
                    Radiation oncologist - Pierre Blanchard, Villejuif (FR)
                    Urologist - Steven Joniau, Leuven (BE)

12:10 - 12:45  Multidisciplinary case discussion: Newly diagnosed Hormone sensitive metastatic PCa
  Moderator and Case presenter: Medical oncologist - Oraianthi Fiste, Athens (GR)
  Case discussants:  Urologist - Axel Merseburger, Lübeck (DE)
                   Radiation oncologist - Stephanie Kroezu, Zurich (CH)

12:45 - 14:00  Lunch break and e-poster viewing

13:00 - 14:00  Lunch Industry session

14:00 - 15:20  Bladder cancer: Bladder preserving strategies in NMIBC (plenary 3)
  Chairs:  Urologist - Morgan Rouprêt, Paris (FR)
14:00 - 14:10 **Use of bio markers in bladder preserving strategies**
Urologist - Paolo Gontero, Turin (IT)
14:10 - 14:20 **Innovative approaches for patients who fail after BCG**
Urologist - Gianluca Giannarini, Udine (IT)
14:20 - 14:30 **BCG or more?**
Urologist - Marco Moschini, Lucerne (CH)
14:30 - 14:40 **How to improve topical therapy**
Urologist - Fred Witjes, Nijmegen (NL)
14:40 - 14:50 **Quality of TURBT**
Urologist - Athanasios Papatsoris, Athens (GR)
14:50 - 15:10 **Discussion**

15:10 – 15:40 **Coffee break and e-poster viewing**

15:40 - 16:00 **EAU Research Foundation session**
Chairs: Urologist – Anders Bjartell, Malmö (SW)
Epidemiologist - Wim Witjes, Arnhem (NL)
15:40 – 15:50 **Update on the Prostate Imaging using MRI +/- contrast Enhancement (PRIME) study**
Urologist - Veeru Kasivisvanathan, London (GB)
15:50 – 16:00 **Establishment of Patient-Derived Tumor Xenografts to test personalized treatment strategies**
Urologist - Maarten Albersen, Leuven (BE)

16:00 - 17:30 **Kidney cancer: Multidisciplinary case discussions (plenary 4)**
Panel: Radiologist – Raymond Oyen, Leuven (BE)
Pathologist - Antonio Lopez-Beltran, Lisbon (PT)
Urologist - Axel Bex, London (GB)
Urologist - Alessandro Volpe, Novara (IT)
Medical oncologist - Laurence Albiges, Villejuif (FR)
16:00 - 16:30 **Multidisciplinary case discussion: Oligometastatic disease**
Case presenter: Urologist - Riccardo Bertolo, Torino (IT)
Moderator: Medical oncologist - Laurence Albiges, Villejuif (FR)
Case discussants: same as panel
16:30 - 17:00 **Multidisciplinary case discussion: When not to do partial nephrectomy**
Case presenter: Urologist - Alessandro Larcher, Milan (IT)
Moderator: Urologist - Axel Bex, London (GB)
Case discussants: same as panel
17:00 - 17:30 **Multidisciplinary case discussion: Alternative treatment modalities for small renal masses**
Case presenter: Urologist - Carmen Mir, Barcelona (ES)
Moderator: Urologist - Alessandro Volpe, Novara (IT)
Case discussants: same as panel
Saturday, 27 November 2021

08:45 - 10:30  New trials update (plenary 5)
Chairs:  Urologist - Marco Moschini, Lucerne (CH)
         Radiation oncologist - Gert De Meerleer, Leuven (BE)

08:45 - 09:00  NIMBUS trial - follow up
Speaker:  Urologist - Marc-Oliver Grimm, Jena (DE)
Discussant:  Urologist - Axel Merseburger, Lübeck (DE)

09:00 - 09:15  Flame trial
Speaker:  Radiation oncologist - Linda Kerkmeijer, Nijmegen (NL)
Discussant:  Radiotherapist - Bradley Pieters, Amsterdam (NL)

09:15 - 09:30  IMvigor130
Speaker:  Medical oncologist - Aristotelis Bamias, Athens (GR)
Discussant:  Medical oncologist - Thomas Powles, London (GB)

09:30 – 09:45  Extended vs limited Pelvic Lymph node dissection in prostate cancer
Speaker:  Urologist - Jean Lestingi, Marco Leite (BR)
Discussant:  Urologist – Ganesh Palapattu, Ann Arbor (US)

09:45- 10:00  CLEAR trial
Speaker:  Urologist - Jens Bedke, Tübingen (DE)
Discussant:  Medical oncologist - Laurence Albiges, Villejuif (FR)

10:00 - 10:30  Discussion

10:30 - 11:00  Coffee break and e-poster viewing

11:00 - 11:50  Multidisciplinary case discussions – Testis (plenary 6)
Panel:  Radiation oncologist - Peter Hoskin, Northwood (GB)
       Medical oncologist - Jan Oldenburg, Oslo (NO)
       Urologist - Christian Fankhauser, Lucerne (CH)
       Pathologist - Maurizio Colecchia, Milan (IT)

11:00 - 11.25  Multidisciplinary case discussion: Active surveillance
Case presenter:  Medical oncologist - Stefanie Fischer, St. Gallen (CH)
Case discussants:  same as panel

11:25 - 11:50  Multidisciplinary case discussion: Poor prognosis or refractory
Case presenter:  Medical Oncologist - Roubini Zakopoulou, Athens (GR)
Case discussants:  Same as panel

11:50 - 12:05  Announcement 3 best abstract posters
Chairs:  Radiation oncologist - Ananya Choudhury, Manchester (GB)
         Urologist - Juan Gomez Rivas, Madrid (ES)
         Medical oncologist - Stefanie Fischer, St. Gallen (CH)

P005 - PSMA-PET- and mpMRI-guided focal radiation dose escalation in primary prostate cancer patients – a planned safety analysis of a two-armed prospective phase II trial (HypoFocal)
Simon Spohn, Freiburg (DE)

P047 - Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis
Constantinos Zamboglou, Freiburg (DE)

P079 - Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1
Arnulf Stenzl, Tübingen (DE)
Oral presentation of the 6 best abstracts

Chairs: Radiation oncologist - Piet Ost, Ghent (BE)
Urologist - Marco Moschini, Lucerne (CH)

O1 - External validation and addition of PSMA-PET to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: An international multicenter study
Dennie Meijer, Amsterdam (NL)

O2 - Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT
Marinus Jan Hagens, Amsterdam (NL)

O3 - Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1
Arnulf Stenzl, Tübingen (DE)

O5 - Updated Overall Survival (OS) with atezolizumab (atezo) monotherapy vs. chemotherapy in untreated locally advanced or metastatic Urothelial Carcinoma (mUC) in the Phase III IMvigor130 study
Aristotelis Bamias, Athens (GR)

O6 - Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial
Marc-Oliver Grimm, Jena (DE)

Lunch break and e-poster viewing

Industry session

Combining immunotherapy with local treatment of GU cancer (plenary 7)

Chairs: Medical oncologist - Maria De Santis, Berlin (DE)
Medical oncologist - Julia Murray, London (GB)
Urologist - Morgan Rouprêt, Paris (FR)

Understanding checkpoint inhibition to improve patient outcome

Immunotherapy and SBRT
Radiation oncologist - Stephanie Kroeze, Zurich (CH)

Peri operative immunotherapy in MIBC
Medical oncologist - Andrea Necchi, Milan (IT)

Radio-immunotherapy for bladder preservation
Radiation oncologist - Ananya Choudhury, Manchester (GB)

The role of surgery in the era of immunotherapy
Urologist - Arnulf Stenzl, Tübingen (DE)

Case based discussion
Case presenter and moderator: Medical oncologist - Maria De Santis, Berlin (DE)

Coffee break and e-poster viewing

Personalised approaches in GU cancers (plenary 8)

Chairs: Pathologist - Antonio Lopez-Beltran, Lisbon (PT)

Circulating tumour DNA for decision making in high risk and metastatic bladder cancer
Researcher - Lars Dyrrskjøt, Aarhus (DK)

Practical considerations for genetic testing in prostate cancer
Medical oncologist - Elena Castro, Malaga (ES)

The new WHO classification of kidney tumours
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 – 16:40</td>
<td>PET/CT: which tracer for which patient?</td>
</tr>
<tr>
<td>16:40 - 17:00</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

Pathologist - Maria Rosaria Raspollini, Florence (IT)

Radiologist - Francesco Ceci, Milan (IT)
Management of recurrent prostate cancer (plenary 9)

Chairs: Radiation oncologist - Michael Pinkawa, Bonn (DE)
       Medical oncologist - Karim Fizazi, Villejuif (FR)
       Urologist - Hein Van Poppel, Leuven (BE)

Salvage radiotherapy: increasing dose and use of ADT?
Case presentation: Radiation oncologist - Charlien Berghen, Leuven (BE)
Yes: Radiation oncologist - Gert De Meerleer, Leuven (BE) (5 min)
No: Urologist - Athanasios Dellis, Athens (GR)
Rebuttal 3 min each (6 min)
Conclusion: Urologist - Hein Van Poppel, Leuven (BE)

Local management of radio recurrent disease
Case presentation: Radiation oncologist - Stephanie Kroeze, Zurich (CH)
Surgery: Urologist - Axel Heidenreich, Cologne (DE)
Focal therapy: Rafael Sanchez Salas, Paris (FR) (5 min)
Rebuttal: 3 min each (6 min)
Conclusion: Urologist - Hein Van Poppel, Leuven (BE) (5 min)

Metastases directed therapy for a recurrent disease, yes or no? debate
Case presentation: Urologist – Nicola Fossati, Milan (IT) (4 min)
Pro: Radiation oncologist - Thomas Zilli, Geneva (CH) (5 min)
Con: Urologist – Ganesh Palapattu, Ann Arbor (US)
Rebuttal: 3 min each (6 min)
Conclusion: Radiation oncologist - Michael Pinkawa, Bonn (DE) (5 min)

Hormone sensitive recurrent disease: How much systemic treatment is necessary?
Case presentation: Urologist - Christian Fankhauser, Lucerne (CH)
ADT and any combination: Medical oncologist - Chris Sweeney, Boston (US) (5 min)
ADT: Urologist - Bertrand Tombal, Brussels (BE) (5 min)
Rebuttal: 3 min each (6 min)
Conclusion: Medical oncologist - Karim Fizazi, Villejuif (FR) (5 min)

Second line CRPC: Peptide Radioligand Therapy vs second line systemic treatment
Case presentation: Medical oncologist – Michail Liontos, Athens (GR) (4 min)
Pro: Medical oncologist – Ignacio Duran, Madrid (ES) (5 min)
Con: Urologist - Urologist - Philip Cornford, Liverpool (GB)
Rebuttal: 3 min each (6 min)
Conclusion: Radiation oncologist - Michael Pinkawa, Bonn (DE) (5 min)

Announcement 3 best abstract posters

Chairs: Urologist - Axel Merseburger, Lübeck (DE)
       Radiation oncologist - Michael Pinkawa, Bonn (DE)

P094 - Adjuvant immunotherapy versus tyrosine kinase inhibitors in patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes
Ekaterina Laukhtina, Vienna (AT)

P154 - Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for non-metastatic urothelial carcinoma of the bladder
Ekaterina Laukhtina, Vienna (AT)

P138 - Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: A contemporary Dutch nationwide cohort study
Anke Richters, Nijmegen (NL)
11:05 - 11:55 Take home messages
11:05 - 11:15 Pathologist - Maurizio Colecchia, Milan (IT)
11:15 - 11:25 Radiation oncologist - Michael Pinkawa, Bonn (DE)
11:25 - 11:35 Urologist - Axel Merseburger, Lübeck (DE)
11:35 - 11:45 Radiologist - Raymond Oyen, Leuven (BE)
11:45 - 11:55 Medical oncologist – Jan Oldenburg, Oslo (NO)

11:55 - 12:00 Closing remarks
Medical oncologist - Aristotelis Bamias, Athens (GR)
Radiation oncologist - Peter Hoskin, Northwood and Manchester (GB)
Urologist - Arnulf Stenzl, Tübingen (DE)